NCT07933848
A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Prifetrastat
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
Secondary (5)
Number of Treatment-Emergent Adverse Events (AE) by Severity
Number of Participants With Clinically Significant Clinical Laboratories Abnormalities
Number of Participants With Clinically Significant Change From Baseline in Blood Pressure or Heart Rate
Number of Participants With Abnormalities in Physical Examination
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings
Arms and interventions
Moderate Renal Impairment (Cohort 1)Experimental
Prifetrastat administered by mouth as a single dose in participants with moderate renal impairment (eGFR = 30-59 mL/min).
Severe Renal Impairment (Cohort 2)Experimental
Prifetrastat administered by mouth as a single dose in participants with severe renal impairment (eGFR \< 30 mL/min).
Normal Renal Function (Cohort 3)Active comparator
Prifetrastat administered by mouth as a single dose in participants with normal renal function (eGFR ≥ 90 mL/min).
Drugs: Prifetrastat
Sites
3 sites in 1 country